ECOR

electroCore experienced several stock-impacting events in the past six months. Positive Q3 2025 earnings led to a stock increase. Preliminary financial guidance anticipated record full-year revenue. Full-year results reported record net sales but also a GAAP net loss, and the CEO announced retirement. A publication highlighted benefits of nVNS, and the first patient was enrolled in a PTSD study. electroCore participated in a healthcare conference, and its stock moved higher. The product line was featured in a documentary, and TAC-STIM was recognized in a safety innovation challenge. Executives presented at an investor summit, and first-quarter results showed record revenue but also a GAAP net loss, with management expressing doubt about the company's ability to continue as a going concern.